|
목적 : To compare the visual and anatomic outcomes between intravitreal injection of ranibizumab and aflibercept on the central macular thickness (CMT) by optical coherence tomography (OCT) as an induction treatment in patients with neovascular age-related macular degeneration (AMD).
방법 : In a single center, prospective, head to head trial, 26 patients were randomly divided into two groups with neovascular AMD to receive 3 consecutive intravitreal injections of ranibizumab or aflibercept with monthly evaluation during induction treatment period. Both groups completed a 3 consecutive injection as an induction phase with monthly intravitreal injection of 0.5mg ranibizumab or 2mg of aflibercept. The primary outcome was monthly changes in the logarithm of minimum angle of resolution (logMAR) and CMT measured using OCT.
결과 : 13 and 13 eyes were recruited as a ranibizumab and aflibercept gorup, respectively. The mean change in CMT was decreased significantly in both group (p<0.05, <0.05) at week 12. In ranibizumab and aflibercept group, mean CMT change from baseline to week 4 and week 12 had no significant difference (p>0.05). But the slope of CMT changes from baseline to week 4 was more steeper trend in aflibercept group than in ranibizumab group. And there is no significant difference in CMT between CMT at week 4 and CMT at week 12 in both group (p>0.05, p>0.05).
결론 : Both ranibizumab and aflibercept were effective anti-VEGF agents in treatment-naïve neovascular ARMD. And a single first injection of aflibercept had more powerful effect in terms of not only CMT decreasing velocity but also drying retina in OCT. And our study also shows the possibility of a single injection treatment protocol in treatment-naïve neovascular ARMD patient as a induction treatment.
|